130 related articles for article (PubMed ID: 1379313)
1. BCR/ABL confers growth factor independence upon a murine myeloid cell line.
Mandanas RA; Boswell HS; Lu L; Leibowitz D
Leukemia; 1992 Aug; 6(8):796-800. PubMed ID: 1379313
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
4. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
[TBL] [Abstract][Full Text] [Related]
5. Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells.
Stewart MJ; Litz-Jackson S; Burgess GS; Williamson EA; Leibowitz DS; Boswell HS
Leukemia; 1995 Sep; 9(9):1499-507. PubMed ID: 7658719
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
Ahmed M; Dusanter-Fourt I; Bernard M; Mayeux P; Hawley RG; Bennardo T; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Turhan AG
Oncogene; 1998 Jan; 16(4):489-96. PubMed ID: 9484838
[TBL] [Abstract][Full Text] [Related]
7. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
[TBL] [Abstract][Full Text] [Related]
8. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Okuda K; Golub TR; Gilliland DG; Griffin JD
Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
[TBL] [Abstract][Full Text] [Related]
9. p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.
Gharehbaghi K; Burgess GS; Collart FR; Litz-Jackson S; Huberman E; Jayaram HN; Boswell HS
Leukemia; 1994 Aug; 8(8):1257-63. PubMed ID: 7520100
[TBL] [Abstract][Full Text] [Related]
10. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB).
Hamdane M; David-Cordonnier MH; D'Halluin JC
Oncogene; 1997 Nov; 15(19):2267-75. PubMed ID: 9393872
[TBL] [Abstract][Full Text] [Related]
11. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line.
Laneuville P; Heisterkamp N; Groffen J
Oncogene; 1991 Feb; 6(2):275-82. PubMed ID: 1705688
[TBL] [Abstract][Full Text] [Related]
12. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
Perrotti D; Bonatti S; Trotta R; Martinez R; Skorski T; Salomoni P; Grassilli E; Lozzo RV; Cooper DR; Calabretta B
EMBO J; 1998 Aug; 17(15):4442-55. PubMed ID: 9687511
[TBL] [Abstract][Full Text] [Related]
13. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
14. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice.
Peters DG; Klucher KM; Perlingeiro RC; Dessain SK; Koh EY; Daley GQ
Oncogene; 2001 May; 20(21):2636-46. PubMed ID: 11420675
[TBL] [Abstract][Full Text] [Related]
15. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
Carlesso N; Griffin JD; Druker BJ
Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
Burgess GS; Williamson EA; Cripe LD; Litz-Jackson S; Bhatt JA; Stanley K; Stewart MJ; Kraft AS; Nakshatri H; Boswell HS
Blood; 1998 Oct; 92(7):2450-60. PubMed ID: 9746785
[TBL] [Abstract][Full Text] [Related]
17. bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors.
Laneuville P; Timm M; Hudson AT
Cancer Res; 1994 Mar; 54(5):1360-6. PubMed ID: 8118826
[TBL] [Abstract][Full Text] [Related]
18. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
19. The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl.
Lionberger JM; Smithgall TE
Cancer Res; 2000 Feb; 60(4):1097-103. PubMed ID: 10706130
[TBL] [Abstract][Full Text] [Related]
20. Expression of BCR - ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation.
Cambier N; Zhang Y; Vairo G; Kosmopoulos K; Metcalf D; Nicola NA; Elefanty AG
Oncogene; 1999 Jan; 18(2):343-52. PubMed ID: 9927191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
